| Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade Z Wang, EG Aguilar, JI Luna, C Dunai, LT Khuat, CT Le, A Mirsoian, ... Nature medicine 25 (1), 141-151, 2019 | 624 | 2019 |
| Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology JA Ajani, TA D’Amico, DJ Bentrem, D Cooke, C Corvera, P Das, ... Journal of the National Comprehensive Cancer Network 21 (4), 393-422, 2023 | 73 | 2023 |
| Surgery versus surveillance for well‐differentiated, nonfunctional pancreatic neuroendocrine tumors: an 11‐year analysis of the national cancer database HA Assi, S Mukherjee, PL Kunz, M Machiorlatti, S Vesely, V Pareek, ... The oncologist 25 (2), e276-e283, 2020 | 63 | 2020 |
| Management of typical and atypical pulmonary carcinoids based on different established guidelines R Gosain, S Mukherjee, SS Yendamuri, R Iyer Cancers 10 (12), 510, 2018 | 62 | 2018 |
| Serotonin pathway in cancer P Balakrishna, S George, H Hatoum, S Mukherjee International journal of molecular sciences 22 (3), 1268, 2021 | 58 | 2021 |
| Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline MA Shah, EB Kennedy, AE Alarcon-Rozas, T Alcindor, AN Bartley, ... Journal of Clinical Oncology 41 (7), 1470-1491, 2023 | 57 | 2023 |
| Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study S Samuel, S Mukherjee, N Ammannagari, VK Pokuri, B Kuvshinoff, ... PLoS One 13 (6), e0198809, 2018 | 55 | 2018 |
| Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States S Shah, R Gosain, A Groman, R Gosain, A Dasari, TR Halfdanarson, ... Cancers 13 (8), 1753, 2021 | 37 | 2021 |
| Socio-demographic disparities in gastric adenocarcinoma: a population-based study N Rana, R Gosain, R Lemini, C Wang, E Gabriel, T Mohammed, ... Cancers 12 (1), 157, 2020 | 36 | 2020 |
| Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection AM D’Alise, N Brasu, C De Intinis, G Leoni, V Russo, F Langone, D Baev, ... Science translational medicine 14 (657), eabo7604, 2022 | 33 | 2022 |
| Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study S Mukherjee, S Ibrahimi, B Khalid, D Roman, D Zhao, R Aljumaily Journal of Oncology Pharmacy Practice 25 (3), 762-764, 2019 | 32 | 2019 |
| Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia S Mukherjee, S Ibrahimi, S John, MM Adnan, T Scordino, MO Khalil, ... Annals of Hematology 96, 1435-1439, 2017 | 27 | 2017 |
| Geographic and demographic features of neuroendocrine tumors in the United States of America: A population‐based study R Gosain, S Ball, N Rana, A Groman, E Gage‐Bouchard, A Dasari, ... Cancer 126 (4), 792-799, 2020 | 22 | 2020 |
| Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature M Gupta, C Sherrow, ME Krone, EM Blais, MJ Pishvaian, EF Petricoin, ... Journal of the National Comprehensive Cancer Network 19 (1), 10-15, 2021 | 19 | 2021 |
| Role of adjuvant chemotherapy in pulmonary carcinoids: an NCDB analysis R Gosain, A Groman, SS Yendamuri, R Iyer, S Mukherjee Anticancer Research 39 (12), 6835-6842, 2019 | 19 | 2019 |
| Exploring the impact of the obesity paradox on lung cancer and other malignancies LJ Nitsche, S Mukherjee, K Cheruvu, C Krabak, R Rachala, ... Cancers 14 (6), 1440, 2022 | 16 | 2022 |
| Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors RV Iyer, B Konda, C Fountzilas, S Mukherjee, D Owen, K Attwood, ... Cancer 126 (16), 3689-3697, 2020 | 14 | 2020 |
| Sequencing systemic therapy pathways for advanced hepatocellular carcinoma: a cost effectiveness analysis C Sherrow, K Attwood, K Zhou, S Mukherjee, R Iyer, C Fountzilas Liver Cancer 9 (5), 549-562, 2020 | 14 | 2020 |
| Personalized dosing versus fixed dosing of immune checkpoint inhibitors: a cost analysis study S Mukherjee, S Ibrahimi, M Machiorlatti, D Roman, R Saleem, A Hassan, ... American Journal of Therapeutics 25 (6), e767-e768, 2018 | 14 | 2018 |
| 410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair … M Overman, M Fakih, D Le, A Shields, K Pedersen, M Shah, S Mukherjee, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 12 | 2021 |
